To print: Select File and then Print from your browser's menu

Title: Glaxo Adds Strong Heart Risk Warning to ADHD Drug

"Glaxo Adds Strong Heart Risk Warning to ADHD Drug"

BETHESDA, M.D. -- August 21, 2006 -- The US Food and Drug Administration (FDA) and GlaxoSmithKline notified healthcare professionals of changes to the BOXED WARNING, WARNINGS and PRECAUTIONS sections of the prescribing information for Dexedrine (dextroamphetamine sulfate), approved for the treatment of Attention-Deficit Hyperactivity Disorder and narcolepsy. The warnings describe reports of sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. [August 04, 2006 - Letter – GlaxoSmithKline http://www.fda.gov/medwatch/safety/2006/Dexedrine_DHCP_Letter.pdf] [June 2006 - Label – GlaxoSmithKline http://www.fda.gov/medwatch/safety/2006/Dexedrine_PI.pdf] SOURCE: Food and Drug Administration

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.